{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:05:47Z","timestamp":1790805947492,"version":"4.1.0"},"reference-count":123,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2016]]},"DOI":"10.5551\/jat.rv16001","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T22:03:56Z","timestamp":1469570636000},"page":"1011-1025","source":"Crossref","is-referenced-by-count":16,"title":["Development of Antisense Drugs for Dyslipidemia"],"prefix":"10.5551","volume":"23","author":[{"given":"Tsuyoshi","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Osaka University"},{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumito","family":"Wada","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Osaka University"},{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists C: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012; 380: 581-590","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H, Yokoyama S: Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674","DOI":"10.5551\/jat.4143"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S: Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 1043-1060","DOI":"10.5551\/jat.14621"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K, Harada-Shiba M, Arai H, Bujo H, Nohara A, Ohta T, Oikawa S, Okada T, Wakatsuki A: Familial hypercholesterolemia. J Atheroscler Thromb, 2014; 21: 6-10","DOI":"10.5551\/jat.20040"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol, 2008; 102: 1K-34K","DOI":"10.1016\/j.amjcard.2008.10.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yamamoto T, Nakatani M, Narukawa K, Obika S: Antisense drug discovery and development. Future Med Chem, 2011; 3: 339-365","DOI":"10.4155\/fmc.11.2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Crooke ST: Progress in antisense technology. Annu Rev Med, 2004; 55: 61-95","DOI":"10.1146\/annurev.med.55.091902.104408"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Crooke TS: Antisense Drug Technologies: Principles, Strategies, And Applications, CRC Press, 2007","DOI":"10.1201\/9780849387951"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Obika S, Nanbu D, Hari Y, Morio K-i, In Y, Ishida T, Imanishi T: Synthesis of 2\u2019-O,4\u2019-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering. Tetrahedron Lett, 1997; 38: 8735-8738","DOI":"10.1016\/S0040-4039(97)10322-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Singh SK, Wengel J: Universality of LNA-mediated high-affinity nucleic acid recognition. Chem Commun, 1998; 1247-1248","DOI":"10.1039\/a801571f"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M, Olsen CE, Wengel J: LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron, 1998; 54: 3607-3630","DOI":"10.1016\/S0040-4020(98)00094-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Prakash TP, Siwkowski A, Allerson CR, Migawa MT, Lee S, Gaus HJ, Black C, Seth PP, Swayze EE, Bhat B: Antisense oligonucleotides containing conformationally constrained 2\u2019,4\u2019-(N-methoxy)aminomethylene and 2\u2019,4\u2019-aminooxymethylene and 2\u2019-O,4\u2019-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. J Med Chem, 2010; 53: 1636-1650","DOI":"10.1021\/jm9013295"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hari Y, Obika S, Ohnishi R, Eguchi K, Osaki T, Ohishi H, Imanishi T: Synthesis and properties of 2\u2019-O,4\u2019-C- methyleneoxymethylene bridged nucleic acid. Bioorg Med Chem, 2006; 14: 1029-1038","DOI":"10.1016\/j.bmc.2005.09.020"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Singh SK, Kumar R, Wengel J: Synthesis of Novel Bicyclo[2.2.1] Ribonucleosides: 2\u2019-Amino- and 2\u2019-Thio-LNA Monomeric Nucleosides. J Org Chem, 1998; 63: 6078- 6079","DOI":"10.1021\/jo9806658"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mitsuoka Y, Kodama T, Ohnishi R, Hari Y, Imanishi T, Obika S: A bridged nucleic acid, 2\u2019,4\u2019-BNA COC: synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2\u2019,4\u2019-BNA COC monomers and RNA-selective nucleic-acid recognition. Nucleic Acids Res, 2009; 37: 1225-1238","DOI":"10.1093\/nar\/gkn1062"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Miyashita K, Rahman SM, Seki S, Obika S, Imanishi T: N-Methyl substituted 2\u2019,4\u2019- BNANC: a highly nucleaseresistant nucleic acid analogue with high-affinity RNA selective hybridization. Chem Commun (Camb), 2007; 3765-3767","DOI":"10.1039\/b707352f"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Yahara A, Shrestha AR, Yamamoto T, Hari Y, Osawa T, Yamaguchi M, Nishida M, Kodama T, Obika S: Amidobridged nucleic acids (AmNAs): synthesis, duplex stability, nuclease resistance, and in vitro antisense potency. Chembiochem, 2012; 13: 2513-2516","DOI":"10.1002\/cbic.201200506"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Seth PP, Allerson CR, Berdeja A, Siwkowski A, Pallan PS, Gaus H, Prakash TP, Watt AT, Egli M, Swayze EE: An exocyclic methylene group acts as a bioisostere of the 2\u2019-oxygen atom in LNA. J Am Chem Soc, 2010; 132: 14942-14950","DOI":"10.1021\/ja105875e"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Seth PP, Allerson CR, Siwkowski A, Vasquez G, Berdeja A, Migawa MT, Gaus H, Prakash TP, Bhat B, Swayze EE: Configuration of the 5\u2019-methyl group modulates the biophysical and biological properties of locked nucleic acid (LNA) oligonucleotides. J Med Chem, 2010; 53: 8309-8318","DOI":"10.1021\/jm101207e"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Crooke TS: Antisense Drug Technologies: Principles, Strategies, And Applications. 2007;","DOI":"10.1201\/9780849387951"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Crooke ST, Lemonidis KM, Neilson L, Griffey R, Lesnik EA, Monia BP: Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J, 1995; 312 (Pt 2): 599-608","DOI":"10.1042\/bj3120599"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Lima WF, Crooke ST: Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry, 1997; 36: 390-398","DOI":"10.1021\/bi962230p"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST: Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem, 2004; 279: 17181-17189","DOI":"10.1074\/jbc.M311683200"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Yamamoto T, Fujii N, Yasuhara H, Wada S, Wada F, Shigesada N, Harada-Shiba M, Obika S: Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice. Nucleic Acid Ther, 2014; 24: 283-290","DOI":"10.1089\/nat.2013.0470"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Pedersen L, Hagedorn PH, Lindholm MW, Lindow M: A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent. Mol Ther Nucleic Acids, 2014; 3: e149","DOI":"10.1038\/mtna.2013.72"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lima WF, De Hoyos CL, Liang XH, Crooke ST: RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery. Nucleic Acids Res, 2016; 44: 3351-3363","DOI":"10.1093\/nar\/gkw065"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Castanotto D, Lin M, Kowolik C, Wang L, Ren XQ, Soifer HS, Koch T, Hansen BR, Oerum H, Armstrong B, Wang Z, Bauer P, Rossi J, Stein CA: A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells. Nucleic Acids Res, 2015; 43: 9350-9361","DOI":"10.1093\/nar\/gkv964"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Liang XH, Shen W, Sun H, Prakash TP, Crooke ST: TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotideinduced nuclear bodies in mammalian cells. Nucleic Acids Res, 2014; 42: 7819-7832","DOI":"10.1093\/nar\/gku484"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Hori S, Yamamoto T, Obika S: XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides. Biochem Biophys Res Commun, 2015; 464: 506-511","DOI":"10.1016\/j.bbrc.2015.06.171"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kurreck J, Wyszko E, Gillen C, Erdmann VA: Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res, 2002; 30: 1911-1918","DOI":"10.1093\/nar\/30.9.1911"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Frieden M, Christensen SM, Mikkelsen ND, Rosenbohm C, Thrue CA, Westergaard M, Hansen HF, Orum H, Koch T: Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res, 2003; 31: 6365-6372","DOI":"10.1093\/nar\/gkg820"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramrat nam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I: Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A, 2015; 112: E1106- 1115","DOI":"10.1073\/pnas.1420955112"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 2009; 19: 92-105","DOI":"10.1101\/gr.082701.108"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Flowers E, Aouizerat BE: MicroRNA associated with dyslipidemia and coronary disease in humans. Physiol Genomics, 2013; 45: 1199-1205","DOI":"10.1152\/physiolgenomics.00106.2013"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Flowers E, Froelicher ES, Aouizerat BE: MicroRNA regulation of lipid metabolism. Metabolism, 2013; 62: 12-20","DOI":"10.1016\/j.metabol.2012.04.009"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Horie T, Baba O, Kuwabara Y, Yokode M, Kita T, Kimura T, Ono K: MicroRNAs and Lipoprotein Metabolism. J Atheroscler Thromb, 2014; 21: 17-22","DOI":"10.5551\/jat.20859"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet, 2010; 11: 597-610","DOI":"10.1038\/nrg2843"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell, 2009; 136: 215-233","DOI":"10.1016\/j.cell.2009.01.002"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Huntzinger E, Izaurralde E: Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet, 2011; 12: 99-110","DOI":"10.1038\/nrg2936"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S: Inhibition of microRNA function by antimiR oligonucleotides. Silence, 2012; 3: 1","DOI":"10.1186\/1758-907X-3-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS: Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos: the biological fate of chemicals, 2007; 35: 460-468","DOI":"10.1124\/dmd.106.012401"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) White PJ, Anastasopoulos F, Pouton CW, Boyd BJ: Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. Expert Rev Mol Med, 2009; 11: e10","DOI":"10.1017\/S1462399409001021"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Lendvai G, Velikyan I, Estrada S, Eriksson B, Langstrom B, Bergstrom M: Biodistribution of 68Ga-labeled LNADNA mixmer antisense oligonucleotides for rat chromogranin-A. Oligonucleotides, 2008; 18: 33-49","DOI":"10.1089\/oli.2007.0104"},{"key":"46","unstructured":"46) Geary RS, Leeds JM, Fitchett J, Burckin T, Truong L, Spainhour C, Creek M, Levin AA: Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos: the biological fate of chemicals, 1997; 25: 1272-1281"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Geary RS, Khatsenko O, Bunker K, Crooke R, Moore M, Burckin T, Truong L, Sasmor H, Levin AA: Absolute bioavailability of 2\u2019-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther, 2001; 296: 898-904","DOI":"10.1016\/S0022-3565(24)38832-9"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA: Pharmacokinetic properties of 2\u2019-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther, 2001; 296: 890-897","DOI":"10.1016\/S0022-3565(24)38831-7"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Hung G, Xiao X, Peralta R, Bhattacharjee G, Murray S, Norris D, Guo S, Monia BP: Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther, 2013; 23: 369-378","DOI":"10.1089\/nat.2013.0443"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Geary RS, Norris D, Yu R, Bennett CF: Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev, 2015; 87: 46-51","DOI":"10.1016\/j.addr.2015.01.008"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Rader DJ, Cohen J, Hobbs HH: Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest, 2003; 111: 1795-1803","DOI":"10.1172\/JCI200318925"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Schonfeld G: Familial hypobetalipoproteinemia: a review. J Lipid Res, 2003; 44: 878-883","DOI":"10.1194\/jlr.R300002-JLR200"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res, 2005; 46: 872-884","DOI":"10.1194\/jlr.M400492-JLR200"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S: Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation, 2008; 118: 743-753","DOI":"10.1161\/CIRCULATIONAHA.108.786822"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Straarup EM, Fisker N, Hedtjarn M, Lindholm MW, Rosenbohm C, Aarup V, Hansen HF, Orum H, Hansen JB, Koch T: Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res, 2010; 38: 7100-7111","DOI":"10.1093\/nar\/gkq457"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010; 375: 998-1006","DOI":"10.1016\/S0140-6736(10)60284-X"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS: Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J, 2015; 36: 566-575","DOI":"10.1093\/eurheartj\/eht549"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Emerging Risk Factors C, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama, 2009; 302: 412-423","DOI":"10.1001\/jama.2009.1063"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Tsimikas S, Hall JL: Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Col Cardiol, 2012; 60: 716-721","DOI":"10.1016\/j.jacc.2012.04.038"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Wiesner P, Tafelmeier M, Chittka D, Choi SH, Zhang L, Byun YS, Almazan F, Yang X, Iqbal N, Chowdhury P, Maisel A, Witztum JL, Handel TM, Tsimikas S, Miller YI: MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res, 2013; 54: 1877-1883","DOI":"10.1194\/jlr.M036343"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML: Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem, 2003; 278: 23260-23269","DOI":"10.1074\/jbc.M302780200"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D, Group of Clinical I: Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med, 2009; 6: 229-239","DOI":"10.1038\/ncpcardio1456"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S: Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Col Cardiol, 2011; 57: 1611-1621","DOI":"10.1016\/j.jacc.2010.10.052"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003; 34: 154-156","DOI":"10.1038\/ng1161"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Li S, Li JJ: PCSK9: A key factor modulating atherosclerosis. J Atheroscler Thromb, 2015; 22: 221-230","DOI":"10.5551\/jat.27615"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Lambert G, Charlton F, Rye KA, Piper DE: Molecular basis of PCSK9 function. Atherosclerosis, 2009; 203: 1-7","DOI":"10.1016\/j.atherosclerosis.2008.06.010"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA: Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Jama, 2012; 308: 2497-2506","DOI":"10.1001\/jama.2012.25790"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med, 2012; 366: 1108-1118","DOI":"10.1056\/NEJMoa1105803"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM: Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res, 2007; 48: 763-767","DOI":"10.1194\/jlr.C600025-JLR200"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Orum H, Elmen J, Seidah NG, Straarup EM: A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One, 2010; 5: e10682","DOI":"10.1371\/journal.pone.0010682"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Lindholm MW, Elmen J, Fisker N, Hansen HF, Persson R, Moller MR, Rosenbohm C, Orum H, Straarup EM, Koch T: PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther, 2012; 20: 376-381","DOI":"10.1038\/mt.2011.260"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Krieg AM: Targeting LDL Cholesterol With LNA. Mol Ther Nucleic Acids, 2012; 1: e6","DOI":"10.1038\/mtna.2011.8"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Yamamoto T, Harada-Shiba M, Nakatani M, Wada S, Yasuhara H, Narukawa K, Sasaki K, Shibata MA, Torigoe H, Yamaoka T, Imanishi T, Obika S: Cholesterollowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids, 2012; 1: e22","DOI":"10.1038\/mtna.2012.16"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology T, Prevention Committee of the Council on Nutrition PA, Metabolism, Council on Arteriosclerosis T, Vascular B, Council on Cardiovascular N, Council on the Kidney in Cardiovascular D: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation, 2007; 115: 450-458","DOI":"10.1161\/CIRCULATIONAHA.106.637793"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Ewald N, Kloer HU: Severe hypertriglyceridemia: an indication for apheresis? Atherosclerosis Supp, 2009; 10: 49-52","DOI":"10.1016\/S1567-5688(09)71810-0"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A: Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol, 2009; 104: 984-991","DOI":"10.1038\/ajg.2009.27"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI: Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med, 2010; 362: 1082-1089","DOI":"10.1056\/NEJMoa0907295"},{"key":"79","doi-asserted-by":"crossref","unstructured":"82) Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Luscher TF, Landmesser U: Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation, 2013; 127: 891-904","DOI":"10.1161\/CIRCULATIONAHA.112.108753"},{"key":"80","doi-asserted-by":"crossref","unstructured":"84) LaRosa JC, Levy RI, Herbert P, Lux SE, Fredrickson DS: A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun, 1970; 41: 57-62","DOI":"10.1016\/0006-291X(70)90468-7"},{"key":"81","doi-asserted-by":"crossref","unstructured":"86) Sehayek E, Eisenberg S: Mechanisms of Inhibition by Apolipoprotein C of Apolipoprotein-E-Dependent Cellular-Metabolism of Human Triglyceride-Rich Lipoproteins through the Low-Density-Lipoprotein Receptor Pathway. J Biol Chem, 1991; 266: 18259-18267","DOI":"10.1016\/S0021-9258(18)55263-7"},{"key":"82","doi-asserted-by":"crossref","unstructured":"87) Kinnunen PK, Ehnolm C: Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett, 1976; 65: 354-357","DOI":"10.1016\/0014-5793(76)80145-7"},{"key":"83","doi-asserted-by":"crossref","unstructured":"89) Goldberg IJ: Clinical review 124: Diabetic dyslipidemia: causes and consequences. Journal Clin Endocrinol Metab, 2001; 86: 965-971","DOI":"10.1210\/jcem.86.3.7304"},{"key":"84","doi-asserted-by":"crossref","unstructured":"91) Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O\u2019Connell JR, Shuldiner AR: A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science, 2008; 322: 1702-1705","DOI":"10.1126\/science.1161524"},{"key":"85","doi-asserted-by":"crossref","unstructured":"93) Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL: Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med, 2014; 371: 2200-2206","DOI":"10.1056\/NEJMoa1400284"},{"key":"86","doi-asserted-by":"crossref","unstructured":"95) Yamamoto T, Yahara A, Waki R, Yasuhara H, Wada F, Harada-Shiba M, Obika S: Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense oligonucleotides in vivo. Org Biomol Chem, 2015; 13: 3757-3765","DOI":"10.1039\/C5OB00242G"},{"key":"87","doi-asserted-by":"crossref","unstructured":"96) Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Na jar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet, 2008; 40: 161-169","DOI":"10.1038\/ng.76"},{"key":"88","doi-asserted-by":"crossref","unstructured":"97) Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, Wahlstrand B, Hedner T, Corella D, Tai ES, Ordovas JM, Berglund G, Vartiainen E, Jousilahti P, Hedblad B, Taskinen MR, Newton-Cheh C, Salomaa V, Peltonen L, Groop L, Altshuler DM, Orho-Melander M: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet, 2008; 40: 189-197","DOI":"10.1038\/ng.75"},{"key":"89","doi-asserted-by":"crossref","unstructured":"98) Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O\u2019Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, Konig IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burtt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA, Jr., Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S: Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010; 466: 707-713","DOI":"10.1038\/nature09270"},{"key":"90","doi-asserted-by":"crossref","unstructured":"99) Minicocci I, Montali A, Robciuc MR, Quagliarini F, Censi V, Labbadia G, Gabiati C, Pigna G, Sepe ML, Pannozzo F, Lutjohann D, Fazio S, Jauhiainen M, Ehnholm C, Arca M: Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J Clin Endocrinol Metab, 2012; 97: E1266-1275","DOI":"10.1210\/jc.2012-1298"},{"key":"91","doi-asserted-by":"crossref","unstructured":"100) Mattijssen F, Kersten S: Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochim Bio phys Acta, 2012; 1821: 782-789","DOI":"10.1016\/j.bbalip.2011.10.010"},{"key":"92","doi-asserted-by":"crossref","unstructured":"101) Liu J, Afroza H, Rader DJ, Jin W: Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J Biol Chem, 2010; 285: 27561-27570","DOI":"10.1074\/jbc.M110.144279"},{"key":"93","doi-asserted-by":"crossref","unstructured":"102) Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M: Silencing of microRNAs in vivo with \u2018antagomirs\u2019. Nature, 2005; 438: 685-689","DOI":"10.1038\/nature04303"},{"key":"94","doi-asserted-by":"crossref","unstructured":"103) Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP: miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab, 2006; 3: 87-98","DOI":"10.1016\/j.cmet.2006.01.005"},{"key":"95","doi-asserted-by":"crossref","unstructured":"104) Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjarn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, Kauppinen S: Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res, 2008; 36: 1153-1162","DOI":"10.1093\/nar\/gkm1113"},{"key":"96","doi-asserted-by":"crossref","unstructured":"105) Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S: LNA-mediated microRNA silencing in nonhuman primates. Nature, 2008; 452: 896-899","DOI":"10.1038\/nature06783"},{"key":"97","doi-asserted-by":"crossref","unstructured":"106) Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ: Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest, 2011; 121: 2921-2931","DOI":"10.1172\/JCI57275"},{"key":"98","doi-asserted-by":"crossref","unstructured":"107) Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM: MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science, 2010; 328: 1566-1569","DOI":"10.1126\/science.1189123"},{"key":"99","doi-asserted-by":"crossref","unstructured":"108) Marquart TJ, Allen RM, Ory DS, Baldan A: miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A, 2010; 107: 12228-12232","DOI":"10.1073\/pnas.1005191107"},{"key":"100","doi-asserted-by":"crossref","unstructured":"109) Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, Khatsenko OG, Kaimal V, Lees CJ, Fernandez-Hernando C, Fisher EA, Temel RE, Moore KJ: Inhibition of miR-33a\/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature, 2011; 478: 404-407","DOI":"10.1038\/nature10486"},{"key":"101","doi-asserted-by":"crossref","unstructured":"110) Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, Esplugues E, Fisher EA, Penalva LO, Moore KJ, Suarez Y, Lai EC, Fernandez-Hernando C: miR-33a\/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A, 2011; 108: 9232-9237","DOI":"10.1073\/pnas.1102281108"},{"key":"102","doi-asserted-by":"crossref","unstructured":"111) Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, FernandezHernando C: MiR-33 contributes to the regulation of cholesterol homeostasis. Science, 2010; 328: 1570-1573","DOI":"10.1126\/science.1189862"},{"key":"103","doi-asserted-by":"crossref","unstructured":"112) Marquart TJ, Wu J, Lusis AJ, Baldan A: Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscl Throm Vas, 2013; 33: 455-458","DOI":"10.1161\/ATVBAHA.112.300639"},{"key":"104","doi-asserted-by":"crossref","unstructured":"113) Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C: Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr<sup>\u2212\/\u2212<\/sup> mice--brief report. Arterioscl Throm Vas, 2013; 33: 1973-1977","DOI":"10.1161\/ATVBAHA.113.301732"},{"key":"105","doi-asserted-by":"crossref","unstructured":"114) Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T: Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscl Throm Vas, 2007; 27: 1706-1721","DOI":"10.1161\/ATVBAHA.107.142570"},{"key":"106","doi-asserted-by":"crossref","unstructured":"115) Krause BR, Princen HM: Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis, 1998; 140: 15-24","DOI":"10.1016\/S0021-9150(98)00141-5"},{"key":"107","doi-asserted-by":"crossref","unstructured":"116) Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF: Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res, 2011; 39: 4795-4807","DOI":"10.1093\/nar\/gkr089"},{"key":"108","doi-asserted-by":"crossref","unstructured":"117) Wagenaar TR, Tolstykh T, Shi C, Jiang L, Zhang J, Li Z, Yu Q, Qu H, Sun F, Cao H, Pollard J, Dai S, Gao Q, Zhang B, Arlt H, Cindhuchao M, Hoffmann D, Light M, Jensen K, Hopke J, Newcombe R, Garcia-Echeverria C, Winter C, Zabludoff S, Wiederschain D: Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells. Nucleic Acids Res, 2015; 43: 1204-1215","DOI":"10.1093\/nar\/gku1367"},{"key":"109","doi-asserted-by":"crossref","unstructured":"118) Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A, Worm J, Hedtjarn M, Souleimanian N, Miller P, Soifer HS, Castanotto D, Benimetskaya L, Orum H, Koch T: Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res, 2010; 38: e3","DOI":"10.1093\/nar\/gkp841"},{"key":"110","doi-asserted-by":"crossref","unstructured":"120) Nishina K, Piao W, Yoshida-Tanaka K, Sujino Y, Nishina T, Yamamoto T, Nitta K, Yoshioka K, Kuwahara H, Yasuhara H, Baba T, Ono F, Miyata K, Miyake K, Seth PP, Low A, Yoshida M, Bennett CF, Kataoka K, Mizusawa H, Obika S, Yokota T: DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun, 2015; 6: 7969","DOI":"10.1038\/ncomms8969"},{"key":"111","doi-asserted-by":"crossref","unstructured":"121) Wada S, Yasuhara H, Wada F, Sawamura M, Waki R, Yamamoto T, Harada-Shiba M, Obika S: Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. J Controll Release, 2016; 226: 57-65","DOI":"10.1016\/j.jconrel.2016.02.007"},{"key":"112","doi-asserted-by":"crossref","unstructured":"122) Nakagawa O, Ming X, Huang L, Juliano RL: Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc, 2010; 132: 8848-8849","DOI":"10.1021\/ja102635c"},{"key":"113","doi-asserted-by":"crossref","unstructured":"123) Ostergaard ME, Yu J, Kinberger GA, Wan WB, Migawa MT, Vasquez G, Schmidt K, Gaus HJ, Murray HM, Low A, Swayze EE, Prakash TP, Seth PP: Efficient Synthesis and Biological Evaluation of 5\u2019-GalNAc Conjugated Antisense Oligonucleotides. Bioconjug Chem, 2015; 26: 1451-1455","DOI":"10.1021\/acs.bioconjchem.5b00265"},{"key":"114","doi-asserted-by":"crossref","unstructured":"124) Prakash TP, Brad Wan W, Low A, Yu J, Chappell AE, Gaus H, Kinberger GA, Ostergaard ME, Migawa MT, Swayze EE, Seth PP: Solid-phase synthesis of 5\u2019-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry. Bioorg Med Chem Lett, 2015; 25: 4127-4130","DOI":"10.1016\/j.bmcl.2015.08.019"},{"key":"115","doi-asserted-by":"crossref","unstructured":"125) Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, Riney S, Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo S, Monia BP, Swayze EE, Seth PP: Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res, 2014; 42: 8796-8807","DOI":"10.1093\/nar\/gku531"},{"key":"116","doi-asserted-by":"crossref","unstructured":"126) Yamamoto T, Sawamura M, Wada F, Harada-Shiba M, Obika S: Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides. Bioorg Med Chem, 2016; 24: 26-32","DOI":"10.1016\/j.bmc.2015.11.036"},{"key":"117","doi-asserted-by":"crossref","unstructured":"127) Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT, Wyrzykiewicz TK, Hung G, Monia BP, Bennett CF: Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res, 2007; 35: 687-700","DOI":"10.1093\/nar\/gkl1071"},{"key":"118","doi-asserted-by":"crossref","unstructured":"128) Hagedorn PH, Yakimov V, Ottosen S, Kammler S, Nielsen NF, Hog AM, Hedtjarn M, Meldgaard M, Moller MR, Orum H, Koch T, Lindow M: Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther, 2013; 23: 302-310","DOI":"10.1089\/nat.2013.0436"},{"key":"119","doi-asserted-by":"crossref","unstructured":"129) van Poelgeest EP, Swart RM, Betjes MG, Moerland M, Weening JJ, Tessier Y, Hodges MR, Levin AA, Burggraaf J: Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis, 2013; 62: 796-800","DOI":"10.1053\/j.ajkd.2013.02.359"},{"key":"120","doi-asserted-by":"crossref","unstructured":"130) Kamola PJ, Kitson JD, Turner G, Maratou K, Eriksson S, Panjwani A, Warnock LC, Douillard Guilloux GA, Moores K, Koppe EL, Wixted WE, Wilson PA, Gooderham NJ, Gant TW, Clark KL, Hughes SA, Edbrooke MR, Parry JD: In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res, 2015; 43: 8638-8650","DOI":"10.1093\/nar\/gkv857"},{"key":"121","doi-asserted-by":"crossref","unstructured":"131) Burel SA, Hart CE, Cauntay P, Hsiao J, Machemer T, Katz M, Watt A, Bui HH, Younis H, Sabripour M, Freier SM, Hung G, Dan A, Prakash TP, Seth PP, Swayze EE, Bennett CF, Crooke ST, Henry SP: Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res, 2016; 44: 2093-2109","DOI":"10.1093\/nar\/gkv1210"},{"key":"122","doi-asserted-by":"crossref","unstructured":"132) Kakiuchi-Kiyota S, Koza-Taylor PH, Mantena SR, Nelms LF, Enayetallah AE, Hollingshead BD, Burdick AD, Reed LA, Warneke JA, Whiteley LO, Ryan AM, Mathialagan N: Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. Toxicol Sci, 2014; 138: 234-248","DOI":"10.1093\/toxsci\/kft278"},{"key":"123","doi-asserted-by":"crossref","unstructured":"133) Seth PP, Jazayeri A, Yu J, Allerson CR, Bhat B, Swayze EE: Structure Activity Relationships of alpha-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals. Mol Ther Nucleic Acids, 2012; 1: e47","DOI":"10.1038\/mtna.2012.34"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/23\/9\/23_RV16001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:27:35Z","timestamp":1749014855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/23\/9\/23_RV16001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":123,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv16001","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}